Search

Abagovomab

Abagovomab is under investigation in clinical trial NCT00418574 (Efficacy Multicentre Trial of Immunotherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients).

MK-4721

MK-4721 is a fully human monoclonal antibody directed to Agensys’ proprietary target Prostate Stem Cell Antigen (PSCA), an antigen expressed at significant levels on tumor cells from the majority of patients

Peginterferon alfacon-1

PEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to a broad range of drug substances such as peptides and proteins including antibody fragments; small

Melitracen

Olendalizumab

Olendalizumab is under investigation in clinical trial NCT01883544 (Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects).

WP-1122

WP-1122 is a prodrug of 2-deoxy-D-glucose (2-DG). It was granted FDA orphan designation for the treatment of glioblastoma multiforme.[L47361]

EDI-200

EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.

Brazikumab

Brazikumab is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease).

HKI-357

Hki 357 is under investigation in clinical trial NCT00550381 (Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy Subjects).

Lunsekimig

Lunsekimig is under investigation in clinical trial NCT06102005 (Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma).